CD47 antibodies and uses thereof for treating cancer
US11180552B2 · kind B2 · utility
0Cited by
18References
33Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2018 |
| Grant date | Nov 23, 2021 |
| Priority date | — |
| Expiry date | Aug 2, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/73
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.